Helus Pharma
About Helus Pharma
Helus Pharma is a clinical-stage biopharmaceutical company developing neuroplastogen therapies and proprietary drug delivery technologies for psychiatric and neurological disorders. Its operating model combines drug discovery, clinical development, intellectual property, and regulatory advancement of novel serotonergic agonists designed to promote neuroplasticity. The company's pipeline includes HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, alongside additional neuroscience programs targeting unmet mental health needs. Helus also develops proprietary delivery technologies intended to improve dosing consistency and treatment administration. Its strategic focus is on advancing differentiated neuropsychiatric therapies through clinical development and commercialization.
Cybin Secures $500 Million Dollar Deal For Psychedelic Drug Development
Cybin (NYSE: CYBN) has entered into a new securities purchase agreement with High Trail Special Situations for up to $500M USD to fund their clinical trials.
Cybin Is Preparing For Psychedelic Assisted Therapies In America
Cybin (NYSE: CYBN) has announced a new partnership with clinical technology company Osmind to accelerate commercial preparations for their novel psychedelic.
Cybin Is Launching Phase III Clinical Trials For Psychedelics
Cybin (NYSE: CYBN) is launching their Phase III clinical trial for their novel psychedelic therapeutic CYB003 for the treatment of major depressive disorder.
Cybin is Seeing Positive Results For Psychedelics in Phase II Clinical Trials
Cybin (NYSE: CYBN) has announced positive data from their Phase II clinical trial for their novel psilocybin analog CYB003.
Hedge Fund Billionaire Steve Cohen is Betting on Psychedelics
Steve Cohen’s hedge fund Point 72, which boasts over $26 billion in assets, disclosed in a new filing they have purchased over 18M shares of Cybin (NYSE:CYBN)
Similar to Helus Pharma
More Companies →Why Helus Pharma Matters
Cybin operates in the psychedelics sector, where biopharmaceutical companies develop clinical applications of psilocybin, DMT and related compounds for psychiatric disorders. This field focuses on rigorous clinical trials, regulatory compliance and pharmaceutical-grade formulations rather than traditional psychedelic use. Research targets treatment-resistant depression, anxiety disorders and other mental health conditions through controlled therapeutic settings. To learn more about this emerging sector, explore psychedelic medicine development and regulatory frameworks.
